Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.60 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550254 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7839929 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL2706071 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL1926493 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7555645 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7555646 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL6818249 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL7547359 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL5050858 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 | |
| SCHEMBL17356699 | 1.00 | CTSK (0.60) | CTSKCTSSNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4093730-A1 | HDAC DEGRADER | University of Leicester (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20170342106-A1 | METHOD OF MAKING PRODRUGS AND TARGETED THERAPEUTIC COMPOUNDS | INSPYR THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3221702-A1 | METHOD OF MAKING PRODRUGS AND TARGETED THERAPEUTIC COMPOUNDS | Inspyr Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081229-A1 | METHOD OF MAKING PRODRUGS AND TARGETED THERAPEUTIC COMPOUNDS | GENSPERA, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2002053572-A1 | DELIVERY SYSTEMS | ALCHEMIA PTY LTD (AU) | 2002-07-11 | — | — | WO | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342106-A1 | METHOD OF MAKING PRODRUGS AND TARGETED THERAPEUTIC COMPOUNDS | CYP21A2, FURIN, CYP26B1 | CTSK 631/4885CTSS 791/4885NOD1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.